Cantor Fitzgerald Maintains Overweight on AbbVie, Raises Price Target to $325
Benzinga Newsdesk 1 hour ago
Analyst RatingsNewsPrice TargetHot
Cantor Fitzgerald analyst Carter Gould maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $290 to $325.
Cantor Fitzgerald analyst Carter Gould maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $290 to $325.